397 related articles for article (PubMed ID: 20576019)
1. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
Luan FL; Samaniego M; Kommareddi M; Park JM; Ojo AO
Transpl Infect Dis; 2010 Dec; 12(6):473-9. PubMed ID: 20576019
[TBL] [Abstract][Full Text] [Related]
2. The effect of different immunoprophylaxis regimens on post-transplant cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients.
Low CY; Hosseini-Moghaddam SM; Rotstein C; Renner EL; Husain S
Transpl Infect Dis; 2017 Oct; 19(5):. PubMed ID: 28613442
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab.
Andrade-Sierra J; Heredia-Pimentel A; Rojas-Campos E; Ramírez Flores D; Cerrillos-Gutierrez JI; Miranda-Díaz AG; Evangelista-Carrillo LA; Martínez-Martínez P; Jalomo-Martínez B; Gonzalez-Espinoza E; Gómez-Navarro B; Medina-Pérez M; Nieves-Hernández JJ
Int J Infect Dis; 2021 Jun; 107():18-24. PubMed ID: 33862205
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus.
Gruber SA; Garnick J; Morawski K; Sillix DH; West MS; Granger DK; El-Amm JM; Alangaden GJ; Chandrasekar P; Haririan A
Clin Transplant; 2005 Apr; 19(2):273-8. PubMed ID: 15740567
[TBL] [Abstract][Full Text] [Related]
5. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.
Deeks ED; Keating GM
Drugs; 2009 Jul; 69(11):1483-512. PubMed ID: 19634926
[TBL] [Abstract][Full Text] [Related]
6. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial.
Carrier M; Leblanc MH; Perrault LP; White M; Doyle D; Beaudoin D; Guertin MC
J Heart Lung Transplant; 2007 Mar; 26(3):258-63. PubMed ID: 17346628
[TBL] [Abstract][Full Text] [Related]
7. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S
Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
[TBL] [Abstract][Full Text] [Related]
8. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus infection in heart transplantation: A single center experience.
Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
[TBL] [Abstract][Full Text] [Related]
10. Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease.
Fayek SA; Beshears E; Lieber R; Alvey N; Sauer A; Poirier J; Hollinger EF; Olaitan OK; Jensik S; Geyston J; Brokhof MM; Hodowanec AC; Hertl M; Simon DM
Transplant Proc; 2016; 48(6):2056-2064.e1. PubMed ID: 27569944
[TBL] [Abstract][Full Text] [Related]
11. Resistant Cytomegalovirus Infection After Renal Transplantation: Literature Review.
Cintra-Cabrera M; Suárez-Benjumea A; Bernal-Blanco G; González-Roncero FM; Toapanta-Gaibor NG; Súñer-Poblet M; Pérez-Valdivia MÁ; Fernández-Cuenca F; Gentil-Govantes MÁ; Rocha-Castilla JL
Transplant Proc; 2018 Mar; 50(2):575-577. PubMed ID: 29579856
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
[TBL] [Abstract][Full Text] [Related]
13. Low-dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti-thymocyte globulin.
Eriksson M; Jokinen JJ; Söderlund S; Hämmäinen P; Lommi J; Lemström K
Transpl Infect Dis; 2018 Jun; 20(3):e12868. PubMed ID: 29512249
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
15. Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction.
Luan FL
Transplant Proc; 2013; 45(1):175-7. PubMed ID: 23267799
[TBL] [Abstract][Full Text] [Related]
16. Rapid T cell repopulation after rabbit anti-thymocyte globulin (rATG) treatment is driven mainly by cytomegalovirus.
Havenith SH; Remmerswaal EB; Bemelman FJ; Yong SL; van Donselaar-van der Pant KA; van Lier RA; Ten Berge IJ
Clin Exp Immunol; 2012 Sep; 169(3):292-301. PubMed ID: 22861369
[TBL] [Abstract][Full Text] [Related]
17. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
[TBL] [Abstract][Full Text] [Related]
18. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients.
Luan FL; Chopra P; Park J; Norman S; Cibrik D; Ojo A
Transplant Proc; 2006 Dec; 38(10):3673-5. PubMed ID: 17175363
[TBL] [Abstract][Full Text] [Related]
20. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]